who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Lawson Gow of The Cannon, Kate Evinger of gBETA, and Michael Lee of Octopus Energy. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — sports tech, energy, and more — recently making headlines in Houston innovation.

Lawson Gow, founder of The Cannon

Lawson Gow is bullish on Houston becoming a sports tech hub. Photo courtesy of The Cannon

Is Houston the next hub for sports tech innovation? Lawson Gow thinks so.

"Sports tech is a thing we can win at. There's no global hub for sports tech — so Houston can do that," Gow says. "We've always had that in our heads as a direction we want the city to head down, so it just makes it so opportunistic to create a space for that kind of innovation at work for the city."

The founder of Houston coworking company, The Cannon, announced last week plans for a sports tech hub in partnership with Braun Enterprises and Gow Media (InnovationMap's parent company). Click here to read more.

Kate Evinger, director of gBETA Houston

Kate Evinger joins the Houston Innovators Podcast to discuss the latest from gBETA Houston. Photo courtesy of gBETA

Most accelerators are focused on growing startups in a specific way toward a specific goal. For gBETA Houston, that goal is toward a new round of funding or another accelerator, says Kate Evinger, director of gBETA Houston on last week's episode of the Houston Innovators Podcast.

"We look at early-stage companies, so those that are pre-seed or seed-stage that are looking for mentorship or support," Evinger says on this week's episode of the Houston Innovators Podcast, "and we help get to that next step whether that's to raise an upcoming round or if they are looking to get into an equity-based accelerator program."

Evinger shares more details on the ongoing cohort on the episode. Click here to read more and stream the show.

Michael Lee, CEO of Octopus Energy US

A $2.23 million deal means a growing presence Texas for Octopus Energy. Photo via LinkedIn

A United Kingdom-founded energy company has expanded yet again in the Texas market. Octopus Energy announced the acquisition of Houston-based Brilliant Energy last week, and it's a huge opportunity for the company says Octopus Energy's United States CEO Michael Lee.

"This is a major moment for us, as we work to bring our 100% renewable energy supply and outstanding technology to more Texans and their homes," he says. Click here to read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News